In vitro antifungal activity of plant extracts on Saprolegnia parasitica from cutaneous lesions of rainbow trout (Oncorhynchus mykiss) eggs

Saprolegnia parasitica Coker is the main agent of saprolegniosis, one of the most important causes of economic losses in the rainbow trout farming industry in Iran. In this work, seven essential oils (2 species) and ethanol extracts (5 species) were tested against a strain of S. parasitica from cutaneous lesions of Oncorhynchus mykiss eggs, using a continuously agitated broth technique that allows both the minimum inhibitory concentration (MIC > 50 %) and the minimum lethal concentration (MLC> 99.9 %) to be evaluated. The essential oils of Thymus daenensis and Thymus khuzestanicum (MIC > 50 % = 0.63 µl ml-1 and MLC> 99.9 % = 22 µl ml-1) and ethanol extracts of Tanacetum parthenium and Mentha longifolia (MIC > 50 % = 31.25 and 62.5 µg ml-1 and MLC> 99.9 % = 600 and 550 µg ml-1, respectively) showed higher inhibition against S. parasitica than the other extracts. In general, our study suggests that natural products derived from some medicinal plants have the potential to be used as health rainbow trout eggs

Flexible, polarization-diverse UWB antennas for implantable neural recording systems

Implanted antennas for implant-to-air data communications must be composed of material compatible with biological tissues. We design single and dual-polarization antennas for wireless ultra-wideband neural recording systems using an inhomogeneous multi-layer model of the human head. Antennas made from flexible materials are more easily adapted to implantation; we investigate both flexible and rigid materials and examine performance trade-offs. The proposed antennas are designed to operate in a frequency range of 2-11 GHz (having S11 below -10 dB) covering both the 2.45 GHz (ISM) band and the 3.1-10.6 GHz UWB band. Measurements confirm simulation results showing flexible antennas have little performance degradation due to bending effects (in terms of impedance matching). Our miniaturized flexible antennas are 12 mm×12 mm and 10 mm×9 mm for single- and dual-polarizations, respectively. Finally, a comparison is made of four implantable antennas covering the 2-11 GHz range: 1) rigid, single polarization, 2) rigid, dual polarization, 3) flexible, single polarization and 4) flexible, dual polarization. In all cases a rigid antenna is used outside the body, with an appropriate polarization. Several advantages were confirmed for dual polarization antennas: 1) smaller size, 2) lower sensitivity to angular misalignments, and 3) higher fidelity

USPOREDBA PRIRODNIH ZEOLITA (KLINOPTILOLITA) KOD ELIMINACIJE METALNIH IONA, S NAGLASKOM NA ELIMINACIJU Cu(II) D-PENICILAMINOM IZ BIOLOŠKIH OKOLIŠA

Clinoptilolite is used as an adsorbent to remove heavy metal cations due to its function as a molecular sieve. This molecular sieve characteristic has made it possible to study the efficiency of clinoptilolite and D-Penicillamine in a comparative way in terms of the adsorption of heavy metals (especially copper) from a biological medium. For this purpose, clinoptilolite was subjected to grinding to produce a homogenized micronized powder in two sizes with d90=75 and 150 μm. Then, initial adsorption tests in an aqueous medium were performed on 10 ppm solutions of iron, zinc, copper, cadmium and nickel cations in single cation solutions, as well as a mixture of cations. In the next step, tests were performed to evaluate the adsorption of Cu2+ on clinoptilolite under different conditions. Experiments have been performed to investigate the effect of pH, temperature (T), adsorbent dosage, time and cation concentration in a simulated biological medium. According to the results, clinoptilolite has a high ability to remove metal cations from aqueous solutions. The 99.71% removal of copper cations by clinoptilolite indicates the high ability of this mineral to remove copper from any environment. In a simulated biological medium at pH=7 and 5, the copper adsorption rate was 98.18% and 97.45% respectively, which indicates the high ability of zeolite to absorb copper cations under biological conditions. An examination of the mass balance calculations has also shown the ability to replace clinoptilolite with penicillamine; 15 mg of clinoptilolite removes 214 mg of Cu from aqueous solutions, which is equivalent to the formation of copper-penicillamine chelate.Klinoptilolit se koristi kao adsorbent za odstranjivanje kationa teških metala djelujući kao molekularno sito. To djelovanje omogućuje izučavanje uspješnosti klinoptilolita i D-penicilamina kod adsorpcije teških metala, posebno bakra, iz biološkoga okoliša. U pokusu je klinoptilolit bio samljeven do razine homogenoga, mikronskoga praha, s česticama dvaju promjera d90 = 75 i 150 μm. Uslijedio je inicijalni adsorpcijski test u vodenome mediju uporabom otopine kationa željeza, cinka, bakra, kadmija i nikla od 10 ppm. Korištene su otopine s jednim kationom i više njih. Zatim je procijenjena adsorpcija Cu2+ na klinoptilolitu u različitim uvjetima. Istražen je utjecaj pH, temperature (T), količine adsorbenta, vremena te koncentracije kationa, sve u simuliranim biološkim medijima. Klinoptilolit ima visoku sposobnost odstranjivanja metalnih kationa iz vodene otopine. Uklanjanje bakra u vrijednosti 99,71% upućuje na veliki potencijal odstranjivanja. Varijacijom pH = 5 i 7 adsorpcijski iznos bio je 97,45 i 98,18 %, što je ponovno uputilo na to da zeoliti dobro adsorbiraju kation bakra u biološkim uvjetima. Načinjen je izračun bilance mase kao potvrda učinkovitosti postupka i u slučajevima kada se klinoptilolit zamijeni s penicilaminom. Tada 15 mg klinoptilolita odvaja 214 mg bakra iz vodene otopine tako da se stvara bakrov-penicilaminov kelat

System level design of a full-duplex wireless transceiver for brain-machine interfaces

We propose a new wireless communication architecture for implanted systems that simultaneously stimulates neurons and record neural responses. This architecture can support large numbers of electrodes (>500), providing 100 Mb/s for the downlink of stimulation signals, and gigabits per second for the uplink of neural recordings. We propose a full-duplex transceiver architecture that shares one antenna for both the ultrawideband (UWB) and the 2.45-GHz industrial, scientific, and medical band. A new pulse shaper is used for the gigabits per second uplink to simplify the transceiver design, while supporting several modulation formats with high data rates. To validate our system-level design for brain-machine interfaces, we present an ex-vivo experimental demonstration of the architecture. While the system design is for an integrated solution, the proof-of-concept demonstration uses discrete components. Good bit error rate performance over a biological channel at 0.5-, 1-, and 2-Gb/s data rates for uplink telemetry (UWB) and 100 Mb/s for downlink telemetry (2.45-GHz band) are achieved

Predictive Molecular Blood Biomarkers in Non-Small Cell Lung Cancer

Background: Lung cancer is characterized by the uncontrolled growth of cells in the lung tissue. The purpose of the present study was to investigate the expression of MUC1 mRNA and CK19 mRNA biomarkers in patients with non-small-cell lung carcinoma (NSCLC).Materials and Methods: In this case-control research, thirty samples of cancer blood, thirty samples of cancer tissue, and the same number of healthy samples were prepared. Samples were collected and RNA was extracted, then cDNA was made and gene expression was measured using Real-Time PCR.Results: Among non-small-cell lung carcinoma patients, the MUC1 mRNA marker was positive for 19 individuals while in the healthy group, it was reported positive in 5 out of 30 individuals. In the patients' group, the CK19 mRNA marker was positive for 16 individuals while in the healthy group, in 6 out of 30 individuals.Conclusion: The MUC1 mRNA and CK19 mRNA as lung cancer tumor markers were reliable and sensitive; however, further studies are recommende

Epitheliod Leiomyoma of the Bladder: An Unusual Case of Irritative and Obstructive Voiding Symptoms

Epitheloid leiomyoma is a very rare subtype of benign mesothelial tumors of the bladder. A 46-year-old female patient presented to our hospital with prolonged dysuria, frequency, and recurrent urinary tract infections. Bimanual examination revealed a mobile, round mass in bladder. There was a round hyperdense intravesical mass near bladder neck in computed tomography (CT) scan that was compatible with her magnetic resonance imaging (MRI). A well defined 3 × 4 centimeter mass was seen in superolateral part of bladder neck during cystoscopy. The patient underwent partial cystectomy and histopathologic findings confirmed the diagnosis of epithelioid leiomyoma. The patient's followup was uneventful in a period of 2 years. Size and anatomic location of this tumor were major factors that affect on treatment

Occupational Stress in Development Musculoskeletal Disorders Among Embassy Personnel of Foreign Countries in Iran at 2015

Concept of occupational stress and its relations with musculoskeletal disorders has been investigated for years. The present study was performed for determining the role of occupational stress in the development of musculoskeletal disorders (MSDs) among embassy personnel of foreign countries in Iran. Study population in the present cross sectional study was 200 embassy personnel of foreign countries in Tehran capital of the Islamic Republic of Iran. Study questionnaires (Nordic Questionnaire; The occupational stress scale) were distributed into participants and finally 161 questionnaires come back to the researchers (response rate: 80.5%). One week and one year period prevalence of musculoskeletal complaints of included embassy personnel were 59.6% and 75.2% respectively. Mean of occupational stress in embassy personnel with musculoskeletal disorders in recent week and year were significantly higher than embassy personnel without musculoskeletal disorders. Smoking and occupational stress score were independent predictor of musculoskeletal disorders. Occupational stress had an impact on development and persistence of WRMSDs among embassy personnel and next studies in this new field will suggest for more detecting actual causes of WRMSDs in these persons and other office workers

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019 : A systematic analysis for the Global Burden of Disease Study 2019

Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

A double burden of malnutrition occurs when individuals, household members or communities experience both undernutrition and overweight. Here, we show geospatial estimates of overweight and wasting prevalence among children under 5 years of age in 105 low- and middle-income countries (LMICs) from 2000 to 2017 and aggregate these to policy-relevant administrative units. Wasting decreased overall across LMICs between 2000 and 2017, from 8.4% (62.3 (55.1–70.8) million) to 6.4% (58.3 (47.6–70.7) million), but is predicted to remain above the World Health Organization’s Global Nutrition Target of <5% in over half of LMICs by 2025. Prevalence of overweight increased from 5.2% (30 (22.8–38.5) million) in 2000 to 6.0% (55.5 (44.8–67.9) million) children aged under 5 years in 2017. Areas most affected by double burden of malnutrition were located in Indonesia, Thailand, southeastern China, Botswana, Cameroon and central Nigeria. Our estimates provide a new perspective to researchers, policy makers and public health agencies in their efforts to address this global childhood syndemic